Kazazian Asset Management’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Kazazian Asset Management’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,957	Closed	-$201K	–	96
2018 Q3	$201K	Hold	2,957	–	–	0.19%	81
2018 Q2	$350K	Sell	2,957 -138	-4%	-$13.8K	0.32%	62
2018 Q1	$256K	Buy	+3,095	New	+$351K	0.27%	68

Other funds holding SRRA

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Kazazian Asset Management's SRRA Position: Q4 2018 in Review

Kazazian Asset Management sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q4 2018, closing a stake of 2,957 shares — an estimated $201K sold.

Kazazian Asset Management first reported a position in SRRA in Q1 2018 and held it in 3 quarters. The position peaked at $350K in Q2 2018. 61 funds tracked by Wall St. Rank hold SRRA as of Q4 2018.

Kazazian Asset Management reported no remaining Sierra Oncology, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Kazazian Asset Management sold 2,957 Sierra Oncology, Inc. Common Stock shares in Q4 2018, an estimated $201K.
Kazazian Asset Management first reported a position in Sierra Oncology, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
Kazazian Asset Management's Sierra Oncology, Inc. Common Stock position peaked at $350K in Q2 2018.
61 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q4 2018.

Based on Kazazian Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.